Germany Pharmaceuticals & Healthcare Report Q1 2015 - New Market Report

While Germany remains a very attractive market for drugmakers, recent regulatory developments intended to reduce healthcare spending will intensify already fierce competition amongst drugmakers , resulting in constrained revenues for less efficient innovators. While recent changes to the reimbursement regime are forecast to bring down retail prices, an ageing population will continue to demand rising volumes of innovative prescription medicines. Additionally, cost-containment initiatives will be moderated by a desire to sustain innovation within an industry key to Germany's positive balance of trade and international standing .

Headline Expenditure Projections

* Pharmaceuticals: Down from EUR40.02bn (USD52.8bn) in 2013 to EU39.95bn (USD53.5bn) in 2014; -0.2% in local currency terms and 1.3% in US dollar terms.
* Healthcare: Up from EUR303.67bn (USD400.85bn) in 2013 to EUR310.13bn (USD415.56bn) in 2014; +2.1% in local currency terms and 3.7% in US dollar terms .

Full Report Details at
- http://www.fastmr.com/prod/912292_germany_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=301

Risk/Reward Rating: In BMI's Q115 Pharmaceutical Risk/Reward Ratings, Germany is ranked as the second most attractive out of the 15 markets covered in the Western European region, losing its place to the United Kingdom.

Key Trends and Developments

* Several firms including GlaxoSmithKline ( GSK), have committed to an ambitious accelerated production schedule for an Ebola vaccine following an emergency meeting of government leaders and the pharmaceutical industry chaired by the World Health Organisation (WHO) in October 2014. With accelerated phase I trials already under way in the United States and United Kingdom, the meeting set targets for trials in Germany and Switzerland, to be launched before the end of 2014. Among the parties to this commitment were Johnson & Johnson, Merck Vaccines, and New Link.
* In July 2014, German drugmaker Boehringer Ingelheim was accused of withholding important evidence from regulators regarding its anticoagulant Pradaxa (dabigatran). The...

The Germany Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Germany Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the German pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Germany to test other views - a key input for successful budgeting and strategic business planning in the German pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Ukraine Pharmaceuticals & Healthcare Report Q1 2015